Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ALEC
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
-83%
0.02
vs 0.12
Q3.23
N/A
-0.53
vs -0.56
Q4.23
N/A
-0.49
vs -0.63
Q1.24
N/A
-0.38
vs -0.55
Q2.24
N/A
-0.40
vs 0.02
Q3.24
N/A
-0.43
vs -0.53
Q4.24
N/A
-0.02
vs -0.49
Q1.25
N/A
-0.41
vs -0.38
Q2.25
N/A
-0.46
vs -0.40
Q3.25
N/A
-0.49
vs -0.43
Sales Growth
YoY
Current
Estimates
Q2.23
-30%
56.2M vs 79.9M
Q3.23
-39%
9.1M vs 14.9M
Q4.23
+5%
15.2M vs 14.4M
Q1.24
-4%
15.9M vs 16.5M
Q2.24
-73%
15.1M vs 56.2M
Q3.24
+68%
15.3M vs 9.1M
Q4.24
+257%
54.2M vs 15.2M
Q1.25
-77%
3.7M vs 15.9M
Q2.25
-82%
2.8M vs 15.1M
Q3.25
-82%
2.8M vs 15.3M
Return on Equity
QoQ
Q2.23
+1%
0.01
vs -0.25
Q3.23
-27%
-0.27
vs 0.01
Q4.23
-31%
-0.31
vs -0.27
Q1.24
-20%
-0.20
vs -0.31
Q2.24
-26%
-0.26
vs -0.20
Q3.24
-35%
-0.35
vs -0.26
Q4.24
-2%
-0.02
vs -0.35
Q1.25
-43%
-0.43
vs -0.02
Institutionnal Ownership
QoQ
Q2.23
145
145
vs 150
-3%
Q3.23
150
150
vs 145
3%
Q4.23
151
151
vs 150
1%
Q1.24
160
160
vs 151
6%
Q2.24
163
163
vs 160
2%
Q3.24
164
164
vs 163
1%
Q4.24
153
153
vs 164
-7%
Q1.25
141
141
vs 153
-8%
Quote Panel
Key Metrics
Forecast
1284%2026-Revenue
-294%2026-EPS
2%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
Keefe, Bruyette & Woods
upgradePrevious: Not converted
2023-12-14
Now: Buy
Morgan Stanley
downgradePrevious: Not converted
2022-09-09
Now: Equal-Weight
globenewswire.com
8 hours ago
globenewswire.com
8 hours ago
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
NASDAQ
Unprofitable
Unprofitable
0.01Â ( 0.66%)
Relative Strenght
16
Volume Buzz
-43%
Earning Acce
No
Dist 52w H.
78%Relative Strength
ALEC
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|